enoxaparin sodium / Generic mfg. - LARVOL DELTA

A Case Report of Unanticipated Difficult Intubation Due to Posterior Tracheal Angulation. (PubMed, Fed Pract) - "A 50-year-old male with a history of chronic cerebral venous sinus thrombosis and taking enoxaparin presented to the emergency department for recurrent headaches...Flexible fiber-optic bronchoscopy was performed to traverse the acute angulation and advance the ETT. Tracheal deviation in the A-P direction should be considered as a cause of difficult ETT advancement, and fiber-optic bronchoscopy should be performed early to diagnose such lesions."

Intubation • Journal • Cardiovascular • Hematological Disorders • Pain • Thrombosis

Safety of Venous Thromboembolism Pharmacological Prophylaxis in Hospitalized Patients With Inflammatory Bowel Disease (VISCOUS Study). (PubMed, J Patient Saf) - "Our findings suggest that there is no increased risk of bleeding in patients admitted with IBD exacerbation receiving pharmacological VTE prophylaxis during the admission period. However, prospective data, including high-risk patients (e.g., patients with cancer and pregnant women), is warranted."

Journal • Cardiovascular • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis • Venous Thromboembolism

Safety and efficacy of apixaban versus enoxaparin in gynecologic cancer patients undergoing open surgery: an open-label randomized controlled trial. (PubMed, Thromb J) - "These findings support apixaban as a viable alternative to enoxaparin in this population. IRCT20220211053991N1."

Journal • Cardiovascular • Gynecologic Cancers • Oncology • Venous Thromboembolism

Saddle Pulmonary Embolism and Deep Vein Thrombosis Following Foot and Ankle Surgery While on Prophylactic Lovenox: A Case Report. (PubMed, J Am Podiatr Med Assoc) - "This medication, surgical intervention, and a period of non-weight bearing are believed to be contributory to the patient's relatively increased hypercoagulable state. This case depicts a rare complication of foot and ankle surgery and highlights the importance of VTE prophylaxis during the postoperative period."

Journal • Cardiovascular • Hematological Disorders • Infertility • Orthopedics • Pulmonary Embolism • Respiratory Diseases • Sexual Disorders • Venous Thromboembolism

Prevalence of Missed Medication Doses and Outcomes of Hospitalized Patients Living with HIV in Uganda. (PubMed, Drug Healthc Patient Saf) - "Missed doses were common across nearly all medications, with omission rates exceeding 80% for ceftriaxone, paracetamol, metronidazole, omeprazole, metoclopramide, and levofloxacin, and approaching 100% for furosemide, co-amoxiclav, ondansetron, enoxaparin, albumin, and artesunate. Missed parenteral medication doses are highly prevalent among hospitalized PLHIV in Uganda. Strengthening medication administration and documentation systems is urgently needed to improve patient safety and outcomes."

Journal • Human Immunodeficiency Virus • Infectious Disease

C3 as a sensitive biomarker of alveolocapillary barrier integrity in acute lung injury: Protective modulation by enoxaparin. (PubMed, Tissue Cell) - "CC16 expression was reduced following LPS exposure, indicating club cell dysfunction and interstitial inflammation, with only partial recovery under ENX. Collectively, these findings identify C3 as a sensitive early biomarker of complement-driven lung injury and support early complement modulation as a promising prophylactic approach in ALI."

Biomarker • Journal • Acute Lung Injury • Cardiovascular • Inflammation • Respiratory Diseases • Venous Thromboembolism • CXCL8 • TNFA

Lung Abscess in a COVID-19 Patient: A Case Report. (PubMed, Adv Biomed Res) - "A treatment regimen, including dexamethasone, enoxaparin, piperacillin/tazobactam, and famotidine intravenous remdesivir was started. The HRCT scan was repeated on the 6th day of admission and showed the same ground-glass opacity as before but the lung abscess had become smaller in size. Altogether, we should be aware of lung abscess as one of the COVID-19 manifestations and complications."

Journal • Infectious Disease • Novel Coronavirus Disease • Pain • Pulmonary Disease • Respiratory Diseases

Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (clinicaltrials.gov) - P4 | N=50 | Completed | Sponsor: Assistance Publique - Hôpitaux de Paris | Recruiting ➔ Completed | Trial completion date: Oct 2026 ➔ Jan 2026 | Trial primary completion date: Jul 2026 ➔ Sep 2025

Trial completion • Trial completion date • Trial primary completion date • Pediatrics • Transplantation • MTHFR

Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay (clinicaltrialsregister.eu) - P1/2 | N=200 | Not yet recruiting | Sponsor: Fakultni Nemocnice Ostrava

New P1/2 trial • Cardiovascular • Heart Failure

Association Between Subcutaneous Medication Administration and ICU Delirium (SCCM 2026) - "The purpose of this study is to determine whether there is an association between ICU delirium and administration of subcutaneous medications like enoxaparin, heparin, and insulin in the ICU. This retrospective chart review included critically ill adults admitted to the ICU for ≥72 hours from January to December 2020... A weakly positive correlation was found between number of subcutaneous medications in the ICU and delirium. Given the stronger correlation with POCG checks, this may be driven by frequency of the mild but repetitive noxious stimuli. Future research should clarify this association and seek to determine whether positive interventions to reduce mild noxious stimuli reduce the incidence of delirium."

Addiction (Opioid and Alcohol) • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Evaluation of a Venous Thromboembolism Prophylaxis Protocol for Trauma Patients (SCCM 2026) - "In response to guideline changes and new evidence, Saint Luke's Hospital (SLH) created a VTE prophylaxis protocol for trauma patients for enoxaparin based on injury and weight... The incidence of VTE in trauma patients at SLH was lower after implementation of a risk-stratified, injury-guided, and weight-based VTE prophylaxis protocol."

Clinical • Cardiovascular • Venous Thromboembolism

Optimization of Venous Thromboembolism Prophylaxis Dosing in Trauma and Ortho Patients (SCCM 2026) - "Enoxaparin weight-based dosing with trough anti-Xa monitoring resulted in a significant reduction in VTE rates at a level II trauma center."

Clinical • Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Challenges in Managing Morbidly Obese Critically Ill Patients (SCCM 2026) - "Treated for pneumonia (meropenem/vancomycin/doxycycline) and empiric enoxaparin (0.67 mg/kg) for suspected PE/DVT. Obesity-driven comorbidities (e.g., diabetes, OSA) contribute to higher death rates, while environmental constraints in diagnostics/therapeutics remain underaddressed. We emphasize the urgent need for bariatric-capable imaging equipment, standardized protocols for pharmacotherapy, and specialized training for ICU teams to mitigate these gaps."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Cough • Diabetes • Genetic Disorders • Immunology • Infectious Disease • Metabolic Disorders • Obesity • Pneumonia • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Septic Shock

Identifying Gaps in High-Risk Pulmonary Embolism Care: A VA Case Analysis (SCCM 2026) - "4 patients were anticoagulated with unfractionated heparin (UFH), and 1 with Enoxaparin... This retrospective study highlights gaps in acute PE prevention, recognition, and management. It emphasizes the need for systematic review of VTE prophylaxis adherence in this patient population, especially those with comorbidities. Multiple society guidelines recommend ST in acute PE with hemodynamic instability, yet this recommendation was not applied to HR-PE patients."

Clinical • Cardiovascular • Pulmonary Embolism • Respiratory Diseases • Venous Thromboembolism

Optimizing Anticoagulant Strategies in Pregnancy-Associated HIT and Acute Stroke in a Real-World Community Setting (THSNA 2026) - "Case Presentation: A 30-year-old gravid 1 para 0 woman with a history of unprovoked lower-extremity deep vein thrombosis (DVT), maintained on rivaroxaban for secondary prophylaxis, was transitioned to LMWH (enoxaparin) at 7 weeks' gestation...Enoxaparin was discontinued, and argatroban was initiated post-EVT, followed by transition to subcutaneous danaparoid and ultimately fondaparinux for ongoing anticoagulation through pregnancy...This case demonstrates that, when supported by coordinated multidisciplinary expertise, community hospitals can effectively deliver highly specialized, patient-centered thrombosis care. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombocytopenia • Thrombosis

Exploratory analysis of intrinsic pathway-triggered thrombin generation inhibition in healthy volunteers and patients post-total knee arthroplasty who received REGN9933A2 and REGN7508CAT (THSNA 2026) - P1, P2 | "Objectives: To explore parameters of FXI inhibition with REGN9933A2 and REGN7508CAT versus placebo in healthy adults, and versus enoxaparin and apixaban in patients post-TKA using a validated, exploratory, ellagic acid-triggered modified TGA. These results indicate that global, intrinsic pathway-triggered TGA methodology is a valuable tool to assess the mechanism of action of monoclonal antibodies targeting FXI. REGN9933A2 and REGN7508CAT demonstrated inhibition of intrinsic pathway-triggered thrombin generation in healthy volunteers and in patients post-TKA. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Clinical • First-in-human • Orthopedics • Pain

Deep Vein Thrombosis Following Calf Hematoma in a Pediatric Patient with Factor VII Deficiency (THSNA 2026) - "By hospital day 1 (HD#1), he was transitioned to prophylactic enoxaparin, and on HD#2, with improvement in clot burden and reduction in hematoma size, rFVIIa infusions were reduced to twice daily while enoxaparin was escalated to therapeutic dosing... This case underscores the clinical complexity of managing concurrent bleeding and thrombotic risks in patients with FVII deficiency. Despite a known bleeding disorder, FVII deficiency does not preclude thrombosis, particularly in the setting of obesity, trauma, and immobilization. Furthermore, this report demonstrates the utility of POC MUSKUS as a noninvasive, real-time imaging modality for safely monitoring hematoma evolution and guiding treatment decisions in patients with coagulopathies."

Clinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Musculoskeletal Diseases • Obesity • Pediatrics • Thrombosis • Venous Thromboembolism

Adequacy of Standard Therapeutic Low–Molecular-Weight Heparin Dosing in Pregnant Women with Prosthetic Heart Valves: An Anti-Factor Xa–Based Evaluation (THSNA Travel Awardee) (THSNA 2026) - "Objectives: To evaluate whether standard therapeutic LMWH dosing (enoxaparin 1 mg/kg twice daily) achieves target anti-factor Xa levels in pregnant women with prosthetic valves or other high-risk cardiac indications... The majority of pregnant women receiving standard weight-based therapeutic LMWH fail to achieve target anti-factor Xa levels, with MVR patients particularly vulnerable to under-anticoagulation. These findings underscore the need for individualized, anti-Xa–guided LMWH dosing strategies in pregnancy, rather than reliance on standard dosing regimens, to minimize the risk of valve thrombosis and other thromboembolic complications. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Clinical • Cardiovascular • Hematological Disorders • Thrombosis

Rivaroxaban as secondary thromboprophylaxis in pediatric patients with digestive malabsorption (THSNA 2026) - "Low molecular weight heparin (LMWH), or enoxaparin, has been the standard of care for pediatric patients requiring VTE prophylaxis. Our case series summarizes three pediatric patients with short bowel syndrome who were treated with rivaroxaban and utilized rivaroxaban peak levels to ensure expected prophylactic ranges were achieved. We used a weight-based pediatric dose recommendation for thromboprophylaxis after the Fontan procedure. In our experience, two patients with short bowel syndrome and chronic CVC were treated with rivaroxaban for secondary thromboprophylaxis for >1 year at varying doses without recurrent VTE or major bleeding events."

Clinical • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Orthopedics • Pediatrics • Short Bowel Syndrome • Thrombocytopenia • Venous Thromboembolism

Effects of Disruption in Venous Thromboembolism Prophylaxis in Burn Patients: A Case-Control Study (SCCM 2026) - "All VTE patients received chemoprophylaxis (86.3% enoxaparin, 13.7% heparin)... In conclusion, %TBSA and central line duration are likely significant risk factors for VTE in burn patients."

Clinical • Cardiovascular • Hematological Disorders • Thrombocytopenia • Venous Thromboembolism

Optimizing Anticoagulation in Pregnant Women with Prosthetic Heart Valves: A Prospective Comparative Study from a Pharmacist-Led Clinic in Pakistan (THSNA 2026) - "Participants were assigned to one of three anticoagulation groups based on clinical decision-making: (1) warfarin, (2) LMWH (e.g., enoxaparin), or (3) UFH. This study highlights the critical need for individualized anticoagulation regimens during pregnancy in women with prosthetic heart valves. LMWH emerges as a safer alternative to warfarin, particularly in the first trimester, and pharmacist-led anticoagulation clinics enhance patient monitoring and outcomes. Our findings underscore the importance of evidence-based protocols tailored to resource-limited settings and aim to inform future clinical guidelines to reduce maternal and fetal morbidity and mortality."

Clinical • Cardiovascular • Hematological Disorders

Managing Neonatal Central Venous Catheter-Related Thrombosis: A Role for Rivaroxaban (THSNA 2026) - "Treatment with anticoagulant medication (heparin, enoxaparin, rivaroxaban) was identified by NLP of medication administration records. In this single-center cohort, rivaroxaban was successfully used for treatment of CVC-RT in NICU patients, with no serious bleeding events and acceptable thrombus outcomes. These findings suggest that rivaroxaban may be a feasible and well-tolerated alternative to traditional parenteral anticoagulation in neonates. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Cardiovascular • Hematological Disorders • Thrombosis • Venous Thromboembolism

Extended Post-Discharge Venous Thromboembolism Prophylaxis After Colorectal Resection: A MarketScan Analysis of 2017–2021 Surgical Outcomes (THSNA 2026) - "Exposure is defined as prophylactic-dose anticoagulant dispensing within 0–7 days post-discharge, including low–molecular-weight heparin (LMWH; e.g., enoxaparin) or direct oral anticoagulants (DOACs; e.g., rivaroxaban or apixaban). This study is expected to provide the most contemporary national evaluation of EPPx utilization and outcomes following colorectal surgery. Findings will support risk-stratified decision-making and may inform guideline refinement for high-risk surgical populations. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Cardiovascular • Venous Thromboembolism

Efficacy and safety of direct oral anticoagulants versus enoxaparin for extended thromboprophylaxis following sleeve gastrectomy. (PubMed, Surg Obes Relat Dis) - "Enoxaparin is associated with both lower thrombosis and bleeding rates compared with apixaban for extended thromboprophylaxis after sleeve gastrectomy."

Journal • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Venous Thromboembolism

EFFECT OF PROLONGED ANTICOAGULATION ON MYOCARDIAL INJURY AFTER PRIMARY PCI FOR STEMI: RIGHT CMR SUBSTUDY (ACC 2026) - "The secondary objective was to evaluate the effect of different anticoagulation regimen (bivalirudin, enoxaparin or unfractionated heparin) on infarct size. The CMR substudy of RIGHT trial demonstrated that prolonged anticoagulation after primary PCI for STEMI did not reduce infarct size."

Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Heart Failure • Reperfusion Injury